Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 11:15:10 2024-05-31 am EDT			5-day change	1st Jan Change
1.64 ^CAD	-.--%		+2.50%	-22.64%

May. 16	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
Mar. 22	Bright Minds Biosciences Inc. announced that it expects to receive $0.05416 million in funding	CI

Bright Minds Biosciences Inc. Announces the Resignation of Doug Williamson from Board of Directors

January 09, 2023 at 04:05 pm EST

Bright Minds Biosciences Inc. announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board.

Latest news about Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 15	CI
Bright Minds Biosciences Inc. announced that it expects to receive $0.05416 million in funding	Mar. 21	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 12	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 29	CI
Bright Minds Biosciences Inc. announced that it has received $0.9 million in funding	Dec. 21	CI
Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding	Dec. 05	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI
Top Midday Gainers	23-08-08	MT
Bright Minds Biosciences on "Positive" qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	23-08-08	MT
Bright Minds Biosciences Brief: Announcing "Positive" qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	23-08-08	MT
Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101	23-08-08	CI
Bright Minds Biosciences Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	23-07-20	MT
Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101	23-07-20	CI
Bright Minds Biosciences Brief: Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	23-07-20	MT
Bright Minds Biosciences Brief: Will Consolidate Its Common Shares On a 5) to 1 Basis; Co's post-Consolidation Shares Expected to Begin Trading on the CSE and The NASDAQ Capital Market on July 14, 2023	23-07-11	MT
Bright Minds Biosciences Announced Proposed Share Consolidation	23-06-22	MT
Bright Minds Biosciences Brief: Announcing Proposed Share Consolidation	23-06-22	MT
Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-15	CI
Bright Minds Biosciences Receives "Favorable" Written Opinion from International Searching Authority for BMB-202	23-04-19	MT
Bright Minds Biosciences Brief: Says Received a "Favorable" Written Opinion from International Searching Authority for BMB-202	23-04-19	MT
Bright Minds Biosciences Inc. Receives Favorable Written Opinion from the International Searching Authority for BMB-202	23-04-19	CI
Bright Minds Biosciences Provides Clinical Program Updates	23-02-27	MT
Bright Minds Biosciences Brief: Providing Clinical Program Updates and Outlines Anticipated Milestones for 2023	23-02-27	MT
Bright Minds Biosciences Inc. Provides Clinical Program Updates	23-02-27	CI
Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director	23-02-17	CI

Chart Bright Minds Biosciences Inc.

Duration

Period

More charts

Company Profile

Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BRIGHT MINDS BIOSCIENCES INC.	-22.64%	5.37M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research